Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline of talk
3. Caspase pathways: intervention points
4. Overview of caspase family members
5. Caspase pathways: apoptotic and inflammation
6. Optimal substrate sequence specificity
7. Peptide based inhibitors: reversible
8. Peptide based inhibitors: irreversible
9. Indications in which caspases have been implicated
10. Which indications are likely?
11. What is myocardial infarction?
12. Caspase inhibition: therapeutic intervention in MI
13. What is a stroke/ischemia?
14. Use of animal models for stroke/ischemia
15. Caspase inhibition: therapeutic intervention-stroke
16. Liver disease
17. Sepsis
18. What is rheumatoid arthritis?
19. Caspase' role in rheumatoid arthritis
20. Psoriasis
21. Structure of generic small molecule inhibitors
22. Generic inhibitors: warhead and aspartic acid (1)
23. Reversible/irreversible warheads
24. Generic inhibitors: warhead and aspartic acid (2)
25. Compounds lacking a P1 aspartic acid (1)
26. Compounds lacking a P1 aspartic acid (2)
27. Noncompetitive binding inhibitors
28. Overview of small molecule efforts: Pfizer
29. Pfizer compounds (1)
30. Pfizer compounds (2)
31. Overview of small molecule efforts: Merck
32. Merck compounds (1)
33. Merck compounds (2)
34. Overview of small molecule efforts: Sunesis
35. Sunesis compounds
36. Sunesis: advancement of molecules
37. Sunesis: caspase-1 inhibitors
38. Overview of small molecule efforts: Idun
39. Idun compounds (1)
40. Idun compounds (2)
41. IDN-6556
42. IDN-6556: clinical progress
43. Overview of small molecule efforts: Vertex
44. Vertex compounds: VX-740
45. VX-740: in-vivo data
46. VX-740: clinical progress
47. Vertex compounds: VX-765
48. Key issues
49. Going forward

Topics Covered

• Apoptotic caspases
• Inflammatory caspases
• Validation of caspase involvement in disease
• Animal models
• Rheumatoid arthritis
• Liver degeneration
• Small molecule drug discovery
• Inhibitor specificity
• Reversible and irreversible binding inhibitors
• Clinical trial data

Links

Series:

• Apoptosis

Categories:

• Cell Biology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Tom O'Brien has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.